Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wirth

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Human Molecular Genetics|October 1, 1995
Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individualsE Hahnen, R Forkert, C Marke, et al.
Geobiology|March 22, 2012
Development of a real-time PCR method for the detection of fossil 16S rDNA fragments of phototrophic sulfur bacteria in the sediments of Lake CadagnoD F Ravasi, S Peduzzi, V Guidi, et al.
Human Genetics|October 28, 1997
Different entities of proximal spinal muscular atrophy within one familyB Wirth, D Tessarolo, E Hahnen, et al.
American Journal of Human Genetics|April 17, 1999
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counselingB Wirth, M Herz, A Wetter, et al.
American Journal of Human Genetics|November 5, 1997
De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counselingB Wirth, T Schmidt, E Hahnen, et al.
Human Molecular Genetics|August 14, 2003
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophyL Brichta, Y Hofmann, E Hahnen, et al.
European Journal of Human Genetics : EJHG|January 1, 1993
Efficiency of various strategies and materials to generate new markers: saturating the region 5q11.2-q13.3 with 30 new randomly distributed clonesB Wirth, J Schönling, A el-Agwany, et al.
Clinical Genetics|January 1, 1989
Childhood manifestation of autosomal dominant polycystic kidney disease: no evidence for genetic heterogeneityA Gal, B Wirth, H Kääriäinen, et al.
Scientific Reports|September 27, 2013
Frequent floods in the European Alps coincide with cooler periods of the past 2500 yearsLukas Glur, Stefanie B Wirth, Ulf Büntgen, et al.
Neurobiology of Disease|June 20, 2022
Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarksA Muinos-Bühl, R Rombo, E Janzen, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Human Molecular Genetics|October 1, 1995
Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individualsE Hahnen, R Forkert, C Marke, et al.
Geobiology|March 22, 2012
Development of a real-time PCR method for the detection of fossil 16S rDNA fragments of phototrophic sulfur bacteria in the sediments of Lake CadagnoD F Ravasi, S Peduzzi, V Guidi, et al.
Human Genetics|October 28, 1997
Different entities of proximal spinal muscular atrophy within one familyB Wirth, D Tessarolo, E Hahnen, et al.
American Journal of Human Genetics|April 17, 1999
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counselingB Wirth, M Herz, A Wetter, et al.
American Journal of Human Genetics|November 5, 1997
De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counselingB Wirth, T Schmidt, E Hahnen, et al.
Human Molecular Genetics|August 14, 2003
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophyL Brichta, Y Hofmann, E Hahnen, et al.
European Journal of Human Genetics : EJHG|January 1, 1993
Efficiency of various strategies and materials to generate new markers: saturating the region 5q11.2-q13.3 with 30 new randomly distributed clonesB Wirth, J Schönling, A el-Agwany, et al.
Clinical Genetics|January 1, 1989
Childhood manifestation of autosomal dominant polycystic kidney disease: no evidence for genetic heterogeneityA Gal, B Wirth, H Kääriäinen, et al.
Scientific Reports|September 27, 2013
Frequent floods in the European Alps coincide with cooler periods of the past 2500 yearsLukas Glur, Stefanie B Wirth, Ulf Büntgen, et al.
Neurobiology of Disease|June 20, 2022
Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarksA Muinos-Bühl, R Rombo, E Janzen, et al.
Pageof 12